Some organoselenium compounds may also modulate the activityof enzymes relevant to neurotransmission, such as acetylcholinesterase(AChE) and monoamine oxidases (MAO). Indeed,selanyl-2,3-dihydrobenzofurans effectively inhibited cerebral MAO-Bactivity in vitro, with compound TFSeB demonstratingthe most pronounced effect. Consideringthat MAO-B inhibitors act as therapeutic agents for AD, reducing oxidativedamage and improving cognitive function, compound TFSeB emerges asa promising candidate for studies focused on developing more effectivetherapies for AD. Here, ACHE is linked to Alzheimer disease.